Targeting Cognition in PTSD: Pregnenolone Augmentation of SSRIs

See brief summary

Inclusion criteria

• 18-65 years of age, any ethnic group, either sex
• DSM-IV diagnosis of PTSD by MINI (see schedule of events)
• No change in SSRI medications for > 4 weeks.
• No anticipated need to alter any psychotropic medications for the 10-week duration of the study.
• Ability to fully participate in the informed consent process, or have a legal guardian able to participate in the informed consent process.

Exclusion criteria

• Unstable medical or neurological illness, including seizures, CVA, prostate or breast cancer
• Use of oral contraceptives or other hormonal supplementation such as estrogen.
• Significant suicidal or homicidal ideation.
• Concomitant medications for medical conditions will be addressed on a case-by-case base to determine if exclusionary.
• Current DSM-IV diagnosis of bipolar disorder, schizophrenia or other psychotic disorder, or cognitive disorder due to a general medical condition; history of substance dependence within the last 3 months
• Female patients who are pregnant or breast-feeding.
• Known allergy to study medication.
• Drugs with a narrow therapeutic index (e.g. thioridazine, mesoridazine, ziprasidone, clozapine, etc.) will be excluded, as suggested by the FDA; patients taking these agents will not be eligible for this study.